Pacer Advisors Inc. Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Pacer Advisors Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,464 shares of the biopharmaceutical company’s stock after purchasing an additional 1,434 shares during the period. Pacer Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $17,304,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Vanguard Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after buying an additional 91,956 shares during the last quarter. Capital World Investors lifted its stake in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares during the last quarter. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Putnam Investments LLC increased its stake in Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after purchasing an additional 24,329 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,111.30.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders have sold 9,270 shares of company stock valued at $10,695,833 over the last quarter. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.4 %

Shares of Regeneron Pharmaceuticals stock opened at $1,145.03 on Monday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The firm has a market cap of $126.17 billion, a price-to-earnings ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company’s 50-day simple moving average is $1,131.75 and its 200-day simple moving average is $1,032.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $8.79 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.